Cargando…

Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission

The principal vector of Lyme disease in the United States is Ixodes scapularis: black legged or deer ticks. There is increased evidence that those infected may be plagued by anxiety or depression as well. Researchers have identified transcripts coding for two putative cytosolic sulfotransferases in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Kenneth, Modestino, Edward J, Febo, Marcelo, Steinberg, Bruce, McLaughlin, Thomas, Fried, Lyle, Baron, David, Siwicki, David, Badgaiyan, Rajendra D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521197/ https://www.ncbi.nlm.nih.gov/pubmed/28736624

Ejemplares similares

Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD
por: McLaughlin, Thomas, et al.
Publicado: (2018)

Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction
por: Blum, Kenneth, et al.
Publicado: (2015)

“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic
por: Blum, Kenneth, et al.
Publicado: (2017)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: “Born Bad”
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z(™) Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2016)

Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS)
por: Blum, Kenneth, et al.
Publicado: (2020)

Critical Analysis of White House Anti-Drug Plan
por: Blum, Kenneth, et al.
Publicado: (2017)

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks
por: Blum, Kenneth, et al.
Publicado: (2019)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality
por: Blum, Kenneth, et al.
Publicado: (2015)

A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”
por: Blum, Kenneth, et al.
Publicado: (2021)

Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z
por: Febo, Marcelo, et al.
Publicado: (2017)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward
por: Blum, Kenneth, et al.
Publicado: (2015)

Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
por: Blum, Kenneth, et al.
Publicado: (2015)

Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
por: Blum, K, et al.
Publicado: (2018)

Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term
por: Blum, Kenneth, et al.
Publicado: (2016)

Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency
por: Edwards, Drew, et al.
Publicado: (2020)

Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake
por: Duquette, Lucien L, et al.
Publicado: (2016)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

The effects of residential dual diagnosis treatment on alcohol abuse
por: Schoenthaler, Stephen J, et al.
Publicado: (2017)

Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis
por: McLaughlin, Thomas, et al.
Publicado: (2015)

Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD)
por: Blum, Kenneth, et al.
Publicado: (2020)

Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
por: Blum, Kenneth, et al.
Publicado: (2022)

Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric
por: BLUM, KENNETH, et al.
Publicado: (2014)

Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits
por: Blum, Kenneth, et al.
Publicado: (2020)

Calvin klein (CK) designer cocktail, new “Speedball” is the “grimm reaper”: Brain dopaminergic surge a potential death sentence
por: Gold, Mark S, et al.
Publicado: (2020)

Putative Dopamine Agonist (KB220Z) Attenuates Lucid Nightmares in PTSD Patients: Role of Enhanced Brain Reward Functional Connectivity and Homeostasis Redeeming Joy
por: McLaughlin, Thomas, et al.
Publicado: (2015)

Evidence of Dopaminergic Processing of Executive Inhibition
por: Badgaiyan, Rajendra D., et al.
Publicado: (2011)

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires
por: Blum, Kenneth, et al.
Publicado: (2021)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual
por: Blum, Kenneth, et al.
Publicado: (2020)

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family
por: Dennen, Catherine A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ild4c7cmf0h9ca8vm7fbjej879